Clinical trials: Renal
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
- Trial name
- NCT02402452
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Renal Transplant Failure and Rejection
A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease.
- Trial name
- MODERNIZE1 (NCT07508787)
- Testing
- Siplizumab, Rabbit anti-thymocyte globulin
- Where
- 14 sites in United States, Brazil and 1 more
- Volunteers
- 120 people
- Sponsor
- Nefro Avillion Clinical Development, LLC
Renal Impairment
Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function
This Phase 1 open label study is being conducted to directly characterize the pharmacokinetic (PK) profiles of Chiglitazar following administration of a single oral dose in subjects with renal impairment compared to subjects with…
- Trial name
- NCT05515458
- Testing
- Chiglitazar
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chipscreen Biosciences, Ltd.
Nephrotic Syndrome
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
- Trial name
- NCT05599815
- Testing
- ADX-629
- Where
- 11 sites in United States
- Sponsor
- Aldeyra Therapeutics, Inc.
Chronic Kidney Diseases, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial.
- Trial name
- RESCUE (NCT03926117)
- Testing
- Ziltivekimab
- Where
- 49 sites in United States
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Renal Insufficiency
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
The objective of this long term study is to prospectively evaluate the incidence of NSF in patients with severe CKD or kidney failure including patients undergoing dialysis (stages 4 and 5 i.e., with an eGFR below 30)who have not…
- Trial name
- NCT00773409
- Where
- United States
- Volunteers
- 405 people
- Sponsor
- Bracco Diagnostics, Inc
Chronic Kidney Disease, Type 2 Diabetes
A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes
This is a 24-week multi-center, double-blind, randomized, exploratory study of bardoxolone methyl treatment in 18 patients with Stage 3 CKD (eGFR greater than or equal to 30.0 to less than 60.0 ml/min/1.73m2) and diabetes to…
- Trial name
- NCT01500798
- Testing
- 20 mg bardoxolone methyl
- Volunteers
- 18 people
- Sponsor
- Biogen
Secondary Hyperparathyroidism, Hemodialysis
Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism
This study is a exploratory comparison of the efficacy and safety of paricalcitol injection with maxacalcitol injection in chronic kidney disease participants receiving hemodialysis with secondary hyperparathyroidism.
- Trial name
- NCT00990704
- Testing
- paricalcitol, maxacalcitol
- Where
- 14 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Abbott
CHF, Renal Disease
Validation of a Sensor for Non-Invasive Measurements
Subjects will be measured with both a sensor and a reference device
- Conditions
- CHF, Renal Disease, Hypertension
- Trial name
- NCT03463148
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Baxter Healthcare Corporation
Renal Impairment
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
This study will be conducted to assess the effect of severe renal impairment on the pharmacokinetics of lemborexant after a single-dose administration.
- Trial name
- NCT03443063
- Testing
- Lemborexant
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Cardiovascular Disease, Chronic Kidney Failure
Effect of HCO1100 on Cardiovascular Function
The purpose of this study is to determine whether high porous membranes are effective in the treatment of cardiovascular events in chronic dialysis patients.
- Trial name
- HicoCARD (NCT01363921)
- Testing
- HCO 1100
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Vantive Health LLC
Healthy
Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers
Study to assess potential different properties of telmisartan, which due to its Vd, should result in stronger "beneficial" effects of AT1 blockade in tissues (e.g.
- Trial name
- NCT02261116
- Testing
- Telmisartan, Candesartan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors
Study of Intermittent OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
- Trial name
- NCT00514306
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 79 people
- Sponsor
- Astellas Pharma Inc
IgA Nephropathy
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
This Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric…
- Trial name
- NCT07770815
- Testing
- Sibeprenlimab, Standard of care
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Carcinoma, Renal Cell
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
This is a Phase 3, open-label, randomized, controlled, multi-national, multi-center, parallel-arm study comparing tivozanib to sorafenib in participants with refractory advanced renal cell carcinoma (RCC).
- Trial name
- NCT02627963
- Testing
- Tivozanib hydrochloride, Sorafenib
- Where
- 191 sites in United States, Belgium and 10 more
- Volunteers
- 350 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Anemia
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
This single arm study will assess the efficacy and safety of subcutaneous Mircera for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with ESA.
- Trial name
- NCT00680563
- Testing
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 22 sites in Argentina, Brazil and 8 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
IgA Nephropathy
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient…
- Trial name
- NCT07541287
- Testing
- JADE101
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Jade Biosciences, Inc.
Ischemia Reperfusion Injury, Cardiac Surgery Associated - Acute Kidney Injury
A Study to Evaluate the Efficacy and Safety of BX-001N in Preventing Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Major Adverse Kidney Events (MAKE)
This is a Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a clinical trial of BX-001N to prevent patients from Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and subsequent Major Adverse Kidney Events…
- Trial name
- NCT07164833
- Testing
- BX-001N Experimental group 1, BX-001N Experimental group 2
- Where
- 8 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- Bilix Co.,Ltd.
Ureteral Calculi, Kidney Stones
Study of Silodosin to Facilitate Passage of Urinary Stones
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
- Conditions
- Ureteral Calculi, Kidney Stones, Urolithiasis
- Trial name
- NCT01144949
- Testing
- silodosin
- Where
- 27 sites in United States
- Volunteers
- 239 people
- Sponsor
- Watson Pharmaceuticals
Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy…
- Trial name
- NCT06158958
- Testing
- ABBV-303, Budigalimab
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 27 people
- Sponsor
- AbbVie